Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesCD56+CD3- NK Cells Following Allogeneic Stem Cell TransplantationPhase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerAtezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferStudy of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCTCollection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy VolunteersEarly Palliative Care and Hematological Cancer PatientsCARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
P1050
P2175
P509
Mechanism of action of lenalidomide in hematological malignanciesThe BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancersHHE determination report no. HETA-79-109-1538, Kelly Springfield Tire Company, Cumberland, MarylandAction mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesHow do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Molecules that target nucleophosmin for cancer treatment: an updateNotch signaling: its roles and therapeutic potential in hematological malignanciesMonoclonal antibodies targeting CD38 in hematological malignancies and beyondSignificance of Polymorphisms and Expression of Enzyme-Encoding Genes Related to Glutathione in Hematopoietic Cancers and Solid TumorsMeta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile NeutropeniaEZH2 in normal hematopoiesis and hematological malignanciesMaster regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignanciesThe roles of stem cell memory T cells in hematological malignanciesThe emerging role of Twist proteins in hematopoietic cells and hematological malignanciesEpstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasmsRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesPharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesMicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tuneAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorLong non-coding RNAs in normal and malignant hematopoiesisAutophagy, autophagy-associated adaptive immune responses and its role in hematologic malignanciesCircRNAs in hematopoiesis and hematological malignanciesEpigenetics in Cancer: A Hematological PerspectiveMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesSerglycin in human cancersImmunotherapy in hematologic malignancies: past, present, and future.Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantationEpigenetics in normal and malignant hematopoiesis: An overview and update 2017.Checkpoint inhibitors in hematological malignanciesMDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantationPentachlorophenol and cancer risk: focusing the lens on specific chlorophenols and contaminants.Targeting p53 by small molecules in hematological malignancies.The molecular basis of myeloid malignancies.Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations.Cancer associated fibroblasts in hematological malignancies.
P921
description
Doença humana
@pt
Krankheit
@de
immune system cancer located i ...... d, bone marrow and lymph nodes
@en
مرض يصيب الإنسان
@ar
name
cancro hematológico
@pt
càncer hematològic
@ca
cáncer hematológico
@es
hematologesche Kriibs
@lb
hematologia kancero
@eo
hematologic cancer
@en
hematologisk kreft
@nn
hémopathie maligne
@fr
minbizi hematologiko
@eu
гемаблястоз
@be-tarask
type
label
cancro hematológico
@pt
càncer hematològic
@ca
cáncer hematológico
@es
hematologesche Kriibs
@lb
hematologia kancero
@eo
hematologic cancer
@en
hematologisk kreft
@nn
hémopathie maligne
@fr
minbizi hematologiko
@eu
гемаблястоз
@be-tarask
altLabel
Cancro de origem sanguínea
@pt
Cancro do sangue
@pt
Hematologic malignancy (disorder)
@en
Hematologic malignancy
@en
blood cancer
@en
cancer a la sangre
@es
cancer du sang
@fr
cancer hematologico
@es
cancer hématologique
@fr
càncer de la sang
@ca
prefLabel
cancro hematológico
@pt
càncer hematològic
@ca
cáncer hematológico
@es
hematologesche Kriibs
@lb
hematologia kancero
@eo
hematologic cancer
@en
hematologisk kreft
@nn
hémopathie maligne
@fr
minbizi hematologiko
@eu
гемаблястоз
@be-tarask
P1748
P279
P2888
P2892
P1995
P2176
P2892
P31
P373
Cancers of the lymph nodes and haematopoiesis
P3841
HP:0004377
P5270
MONDO:0002334